Comparative Associations of Nonalcoholic Fatty Liver Disease and Metabolic Dysfunction–Associated Fatty Liver Disease With Coronary Artery Calcification: A Cross-Sectional and Longitudinal Cohort Study

Background: In cross-sectional and retrospective cohort studies, we examined comparative associations between nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction–associated fatty liver disease (MAFLD) and risk of having or developing coronary artery calcification (CAC). Methods: Participants who had health examinations between 2010 and 2019 were analyzed. Liver ultrasonography and coronary artery computed tomography were used to diagnose fatty liver and CAC. Participants were divided into a MAFLD and no-MAFLD group and then NAFLD and no-NAFLD groups. Participants were further divided into no fatty liver disease (reference), NAFLD-only, MAFLD-only, and both NAFLD and MAFLD groups. Logistic regression modeling was performed. Cox proportional hazard model was used to examine the risk of incident CAC in participants without CAC at baseline and who had at least two CAC measurements. Results: In cross-sectional analyses, 162 180 participants were included. Compared with either the no-NAFLD or no-MAFLD groups, the NAFLD and MAFLD groups were associated with a higher risk of prevalent CAC (NAFLD: adjusted odds ratio [OR], 1.34 [95% CI, 1.29–1.39]; MAFLD: adjusted OR, 1.44 [95% CI, 1.39–1.48]). Among the 4 groups, the MAFLD-only group had the strongest association with risk of prevalent CAC (adjusted OR, 1.60 [95% CI, 1.52–1.69]). Conversely, the NAFLD-only group was associated with a lower risk of prevalent CAC (adjusted OR, 0.76 [95% CI, 0.66–0.87]). In longitudinal analyses, 34 233 participants were included. Compared with either the no-NAFLD or no-MAFLD groups, the NAFLD and MAFLD groups were associated with a higher risk of incident CAC (NAFLD: adjusted hazard ratio, 1.68 [95% CI, 1.43–1.99]; MAFLD: adjusted hazard ratio, 1.82 [95% CI, 1.56–2.13]). Among these 4 groups, the MAFLD-only group had the strongest associations with risk of incident CAC (adjusted hazard ratio, 2.03,[95% CI, 1.62–2.55]). The NAFLD-only group was not independently associated with risk of incident CAC (adjusted hazard ratio, 0.88 [95% CI, 0.44–1.78]) Conclusions: Both NAFLD and MAFLD are significantly associated with an increased prevalence and incidence of CAC. These associations tended to be stronger for MAFLD.

[1]  K. Sung,et al.  Association of Glycosylated Hemoglobin Level and Cancer-Related Mortality in Patients without Diabetes , 2022, Journal of clinical medicine.

[2]  H. Tilg,et al.  Comparative effects of non-alcoholic fatty liver disease and metabolic dysfunction-associated fatty liver disease on risk of incident cardiovascular events: a meta-analysis of about 13 million individuals , 2022, Gut.

[3]  Xin-Lei Zhang,et al.  Promoting the term MAFLD: China in action. , 2022, The lancet. Gastroenterology & hepatology.

[4]  A. Chait,et al.  Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: A Scientific Statement From the American Heart Association. , 2022, Arteriosclerosis, thrombosis, and vascular biology.

[5]  K. Sung,et al.  Association between physical activity and insulin resistance using the homeostatic model assessment for insulin resistance independent of waist circumference , 2022, Scientific Reports.

[6]  M. Zheng,et al.  Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease , 2022, Journal of clinical and translational hepatology.

[7]  Y. Fouad,et al.  Arabic Association for the Study of Diabetes and Metabolism (AASD) endorsing the MAFLD definition of fatty liver disease. , 2021, Journal of hepatology.

[8]  M. Zheng,et al.  Metabolic-associated fatty liver disease and major adverse cardiac events in patients with chronic coronary syndrome: a matched case–control study , 2021, Hepatology International.

[9]  C. Byrne,et al.  Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis. , 2021, The lancet. Gastroenterology & hepatology.

[10]  J. Lima,et al.  Physical activity and the progression of coronary artery calcification , 2021, Heart.

[11]  R. D. de Knegt,et al.  Metabolic dysfunction–associated fatty liver disease improves detection of high liver stiffness: The Rotterdam Study , 2021, Hepatology.

[12]  Ming Yan,et al.  The Chinese Society of Hepatology position statement on the redefinition of fatty liver disease. , 2021, Journal of hepatology.

[13]  R. Zheng,et al.  The Progression and Regression of Metabolic Dysfunction-associated Fatty Liver Disease are Associated with the Development of Subclinical Atherosclerosis: A Prospective Analysis. , 2021, Metabolism: clinical and experimental.

[14]  P. Joshi,et al.  Very High Coronary Artery Calcium (≥1000) and Association With Cardiovascular Disease Events, Non–Cardiovascular Disease Outcomes, and Mortality , 2021, Circulation.

[15]  A. Dhawan,et al.  NAFLD to MAFLD in adults but the saga continues in children: an opportunity to advocate change.: Letter regarding "A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement". , 2021, Journal of hepatology.

[16]  M. Zheng,et al.  Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. , 2021, Hepatobiliary surgery and nutrition.

[17]  Yong‐ho Lee,et al.  Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[18]  M. Blaha,et al.  Coronary Artery Calcium Scoring: New Insights into Clinical Interpretation-Lessons from the CAC Consortium. , 2020, Radiology. Cardiothoracic imaging.

[19]  M. Buman,et al.  World Health Organization 2020 guidelines on physical activity and sedentary behaviour , 2020, British Journal of Sports Medicine.

[20]  M. Zheng,et al.  MAFLD and risk of CKD. , 2020, Metabolism: clinical and experimental.

[21]  M. Silva,et al.  The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. , 2020, The lancet. Gastroenterology & hepatology.

[22]  V. Wong,et al.  The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease , 2020, Hepatology International.

[23]  B. Staels,et al.  Dysregulated lipid metabolism links NAFLD to cardiovascular disease , 2020, Molecular metabolism.

[24]  T. Goeser,et al.  NAFLD and cardiovascular diseases: a clinical review , 2020, Clinical Research in Cardiology.

[25]  O. Hamdy,et al.  Nonalcoholic fatty liver disease and type 2 diabetes: where do Diabetologists stand? , 2020, Clinical Diabetes and Endocrinology.

[26]  H. Tilg,et al.  NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications , 2020, Gut.

[27]  Sanjiv J. Shah,et al.  Longitudinal Association of Non‐Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study , 2020, Journal of the American Heart Association.

[28]  Jaeseung Kang,et al.  Corrigendum: 2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea , 2019, Journal of obesity & metabolic syndrome.

[29]  J. Kang,et al.  2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea , 2019, Journal of obesity & metabolic syndrome.

[30]  S. Wild,et al.  Non alcoholic fatty liver disease and risk of incident diabetes in subjects who are not obese. , 2019, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[31]  S. Wild,et al.  Alcoholic and non-alcoholic fatty liver disease and associations with coronary artery calcification: evidence from the Kangbuk Samsung Health Study , 2018, Gut.

[32]  M. Budoff,et al.  Coronary Calcium Score and Cardiovascular Risk. , 2018, Journal of the American College of Cardiology.

[33]  S. Wild,et al.  Development of new fatty liver, or resolution of existing fatty liver, over five years of follow-up, and risk of incident hypertension. , 2014, Journal of hepatology.

[34]  K. Sung,et al.  Arterial stiffness, fatty liver and the presence of coronary artery calcium in a large population cohort , 2013, Cardiovascular Diabetology.

[35]  D. Bowden,et al.  Coronary Calcium Score Predicts CardiovascularMortality in Diabetes Diabetes Heart Study , 2012 .

[36]  B. Draznin,et al.  Insulin attenuates vascular smooth muscle calcification but increases vascular smooth muscle cell phosphate transport. , 2007, Atherosclerosis.

[37]  N. Chen,et al.  High glucose increases the expression of Cbfa1 and BMP-2 and enhances the calcification of vascular smooth muscle cells. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[38]  S. Morony,et al.  Hyperlipidemia Promotes Osteoclastic Potential of Bone Marrow Cells Ex Vivo , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[39]  C. Nishida,et al.  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies , 2004, The Lancet.

[40]  R. Detrano,et al.  Quantification of coronary artery calcium using ultrafast computed tomography. , 1990, Journal of the American College of Cardiology.